|
Originally published In Press as doi:10.1074/jbc.M201737200 on April 10, 2002
J. Biol. Chem., Vol. 277, Issue 28, 25001-25010, July 12, 2002
Differential Regulation of Gene Expression by PITX2 Isoforms*
Carol J.
Cox ,
Herbert M.
Espinoza ,
Bryan
McWilliams ,
Kimberly
Chappell ,
Lisa
Morton ,
Tord A.
Hjalt§,
Elena V.
Semina§, and
Brad A.
Amendt ¶
From the Department of Biological Science, The
University of Tulsa, Tulsa, Oklahoma 74104-3189 and the
§ Department of Pediatrics, The University of Iowa, Iowa
City, Iowa 52242
Received for publication, February 20, 2002, and in revised form, April 3, 2002
 |
ABSTRACT |
Three major PITX2 isoforms are differentially
expressed in human, mice, zebrafish, chick, and frog tissues. To
demonstrate differential regulation of gene expression by these
isoforms we used three different promoters and three cell lines.
Transient transfection of Chinese hamster ovary, HeLa, and LS-8 cell
lines revealed differences in PITX2A and PITX2C activation of the
PLOD1 and Dlx2 promoters, however, PITX2B is
inactive. In contrast, PITX2B actives the pituitary-specific
Prolactin promoter at higher levels than either PITX2A or
PITX2C. Interestingly, co-transfection of either PITX2A or
PITX2C with PITX2B results in a synergistic activation of the PLOD1 and Dlx2 promoters.
Furthermore, PITX2 isoforms have different transcriptional activity
dependent upon the cells used for transfection analysis. We have
isolated a fourth PITX2 isoform (PITX2D)
expressed only in humans, which acts to suppress the transcriptional
activity of the other PITX2 isoforms. Electrophoretic mobility shift
assays and glutathione S-transferase pull-down experiments
demonstrated that all isoforms interact with PITX2D and that PITX2B
forms heterodimeric complexes with PITX2A and PITX2C. Our research
provides a molecular basis for differential gene regulation through the
expression of PITX2 isoforms. PITX2 isoform activities are both
promoter- and cell-specific, and our data reveal new mechanisms for
PITX2-regulated gene expression.
 |
INTRODUCTION |
The PITX genes are members of the bicoid class of the
homeodomain proteins. These have a lysine residue at position nine of the third helix and are especially noteworthy for a role in both DNA
and RNA binding (1-3). PITX2 was identified by positional cloning of the 4q25 locus in patients with Axenfeld-Rieger syndrome (4). Patients diagnosed with classical Rieger syndrome have PITX2 mutations, mostly clustered in the homeodomain (3-5).
The mouse Pitx2 gene was subsequently cloned from a
pituitary library (6). This gene has been cloned by other groups and
assigned various names (Ptx2, Otlx2,
Brx1, and ARP1) (7-9). Pitx2 has been
shown to be expressed in the brain, heart, pituitary, mandibular and
maxillary regions, eye, and umbilicus (4, 6, 7). Recent reports using
genetic and epigenetic studies and Pitx2 knockout mice have
demonstrated that this gene product is required for the proper
development of the embryo (6, 10-19). Several laboratories have shown
that Pitx2 is a mediator of left-right signaling in
vertebrates. Epigenetic studies suggested a role for Pitx2
in the determination of vertebrate heart and gut looping (10, 11,
13-16). The analysis of Pitx2 / homozygous
knockout mice reveals that Pitx2 is required for normal heart morphogenesis, development of the mandibular and maxillary facial
prominences, and normal tooth and pituitary development (17-19).
However, Pitx2 /+ heterozygous mice display
certain defects in embryogenesis as seen with the homozygous mice (17,
19). A small fraction of heterozygous mice exhibit anterior chamber
defects of the eye and heart defects (17). These mice also failed to
close the ventral body wall consistent with omphalocele found in Rieger patients (17). Rieger syndrome results from haploinsufficiency consistent with some of the defects seen in
Pitx2 /+ heterozygous mice (17, 20).
We and others have identified three major PITX2 isoforms
produced by alternative splicing and use of different promoters (4, 6,
9, 21, 22). PITX2A and PITX2B are generated by
alternative splicing mechanisms, and PITX2C uses an
alternative promoter located upstream of exon 4 (see Fig. 1 below). All
isoforms contain dissimilar N-terminal domains, whereas the homeodomain
and C-terminal domains are identical. The C-terminal domain contains a
highly conserved 14-amino acid region described in the homeobox genes
Otp and aristaless (4, 6), which is called the
OAR (Otp and aristaless) domain. Recent reports
have provided evidence of Pitx2 isoform regulation in
left-right asymmetry (23-25). Epigenetic and genetic studies reveal
that tissue and organ developments are differentially regulated by
Pitx2a and Pitx2c isoforms. In the chick it
appears that Pitx2c plays a crucial role in the left-right
axis determination and rightward heart looping during chick
embryogenesis (25). However, these researchers were unable to detect
the Pitx2b isoform in chicks. Zebrafish are somewhat
different in that Pitx2a has a greater impact on cardiac
symmetry than Pitx2c (23). In Zebrafish Pitx2c is
asymmetrically expressed in the left dorsal diencephalon and developing
gut, whereas Pitx2a is seen in the left heart primordium. Eloquent experiments in mice that were defective in Pitx2a
and Pitx2b expression demonstrate that different organs have
distinct requirements for Pitx2c dosage (24). These
researchers have shown that lower levels of Pitx2c
expression were required for cardiac atria and higher levels for
duodenum and lung development. In contrast, other investigators have
reported expression of Pitx2c and Pitx2b but not
Pitx2a in mice and frogs (26). They report overlapping and
distinct patterns of Pitx2 expression in the lateral plate
mesoderm, heart, gut, cement gland, head mesenchyma, pituitary gland,
branchial arches, myotome, and muscles. Pitx2c and
Pitx2b were expressed in the head region of mice, and
overlapping expression patterns were seen in the brain of frogs.
However, they report only Pitx2c expression was observed
during heart development in both the mouse and frog (26). Other
experiments in mice have shown Pitx2 expression in the
odontogenic epithelium, and it is the first transcriptional marker of
tooth development (27). More recently, we have shown that Pitx2 protein
is restricted to the developing dental epithelium (28). Altogether
these data demonstrate that Pitx2 isoforms are required
either separately or in overlapping domains and in different doses to
regulate normal vertebrate heart, lung, brain, tooth, pituitary, and
gut development. However, the biochemical/molecular mechanisms of these
effects have not been determined.
Target genes for PITX2 have been described for the pituitary; the
Prolactin gene is synergistically activated by Pit-1 and PITX2 (3). Other pituitary-specific Pitx2 target genes have also been
described (29). However, we have now identified two genes outside of
the pituitary that are specifically regulated by PITX2. We have shown
that PITX2 regulates procollagen lysyl hydroxylase (PLOD)
and Dlx2 gene expression (30, 31). The PLOD1 gene
encodes an enzyme responsible for hydroxylizing lysines in collagens
that plays a role in specifying the extracellular matrix and provides a
foundation for the morphogenesis of tissues and organs. The
Dlx2 gene encodes a transcription factor expressed in the
mesenchymal and epithelial cells of the mandibular and maxillary
regions and expressed in the diencephalon. Dlx2, a member of
the distal-less gene family, has been established as a regulator of
branchial arch development (32, 33). Homozygous mutants of
Dlx2 have abnormal development of forebrain cells and
craniofacial abnormalities in developing neural tissue. Dlx
genes exhibit both sequential and overlapping expression, implying that
temporo-spatial regulation of Dlx genes are tightly
regulated (34). Pitx2 and Dlx2 genes are
expressed in the same tissues early during development.
These reports establish that the PITX2 family of
bicoid-like homeodomain genes are key regulators of
important development processes and are required to regulate specific
genes during embryogenesis. Our studies demonstrate differential
activation of the PLOD1 and Dlx2 promoters by
PITX2 isoforms in several cell lines. We demonstrate synergism between
PITX2 isoforms, and their activities appear to be
promoter-dependent. We report the identification of a new PITX2 isoform (PITX2D) generated by the
PITX2C alternative promoter and differential splicing (Fig.
1). We have only observed this isoform expressed in humans, and it was
identified from a human craniofacial library. The PITX2D isoform acts
to down-regulate the transcriptional activities of PITX2A and PITX2C.
All isoforms can form homodimers, and heterodimers are formed with
PITX2B. We demonstrate new regulatory mechanisms for the fine-tuning of PITX2 transcriptional activity that is required for normal development. Our data provide a molecular/biochemical basis for the developmental regulation of organ and tissue development by PITX2 isoforms reported in humans, zebrafish, chicks, frogs, and mice.
 |
MATERIALS AND METHODS |
Expression and Purification of GST-PITX2 Fusion
Proteins--
The PITX2A isoform was PCR-amplified from a
cDNA clone as described (3). The PITX2B, PITX2C, and PITX2D
isoforms were PCR-amplified from cDNA clones provided by Drs. Elena
Semina and Jeff Murray (Department of Pediatrics, University of Iowa).
The 5'-primers all contained the initiation codon and a unique
SalI site, whereas the 3'-antisense primer contained PITX2
sequences downstream of the stop codon and a unique NotI
site (5'-GTACTGCAGATGCGGCCGCAGCATAATTCCCAGTC-3') to
facilitate cloning into the pGEX6P-2
GST1 vector (Amersham
Biosciences) as previously described (3, 35). The 5'-primers were
unique for each isoform and consisted of the following: PITX2B
(5'-CGTCGTCGACATGGAGACCAATTGTCGC-3'), PITX2C
(5'-CGTCGTCGACATGAACTGCATGAAAGGC-3'), PITX2D
(5'-CGTCGTCGACATGTCCACACGCGAAGAA-3'). All pGST-PITX2 plasmids
were confirmed by DNA sequencing. The plasmids were transformed
into BL21 cells. Proteins were isolated as described previously (3).
PITX2 proteins were cleaved from the GST moiety using 80 units of
PreScission Protease (Amersham Biosciences) per milliliter of
glutathione-Sepharose. The cleaved proteins were analyzed on
SDS-polyacrylamide gels and quantitated by the Bradford protein assay
(Bio-Rad).
Electrophoretic Mobility Shift Assay--
Complementary
oligonucleotides containing the Dlx2 bicoid and
bicoid-like sites with flanking partial BamHI
ends were annealed and filled with Klenow polymerase to generate
32P-labeled probes for EMSAs, as described previously (31).
Standard binding assays were performed as previously described (35). The bacteria-expressed and -purified PITX2 proteins were used in the
assays at the indicated amounts. The samples were electrophoresed, visualized, and quantitated as described previously, except
quantitation of dried gels was performed on the Molecular Dynamics
Storm PhosphorImager (Amersham Biosciences) (31).
GST-PITX2 Pull-down and Western Blot Assays--
Immobilized
GST-PITX2D fusion protein was prepared as described above and suspended
in binding buffer (20 mM Hepes, pH 7.5, 5% glycerol, 50 mM NaCl, 1 mM EDTA, 1 mM
dithiothreitol, 1% milk, and 400 µg/ml ethidium bromide). Purified
bacteria-expressed PITX2 proteins (200 ng) were added to 5 µg of
immobilized GST-PITX2D fusion proteins or GST in a total volume of 100 µl and incubated for 30 min at 4 °C. The beads were pelleted and
washed four times with 200 µl of binding buffer. The bound proteins
were eluted by boiling in SDS-sample buffer and separated on a 12.5%
SDS-polyacrylamide gel. Approximately 200 ng of purified PITX2 proteins
were analyzed in separate Western blots. Following SDS-gel
electrophoresis, the proteins were transferred to polyvinylidene
difluoride filters (Millipore), immunoblotted, and detected using PITX2
antibody P2R10 (28, 31) and ECL reagents from Amersham Biosciences.
Cloning of the PITX2D Isoform--
The homeobox sequence of the
PITX2 gene was PCR-amplified using the primers, sense,
5'-caggggaagaatgaggacgt-3', and antisense, 5'-gaagccattcttgcatagct-3',
and the PITX2A plasmid as a template (4). The 175-bp fragment
containing sequences of the first exon of the PITX2D isoform was
PCR-amplified using the primers, sense, 5'-ctgagctgcggcaaggc-3', and
antisense, 5'-ggcagccctgacagagatg-3', and the PITX2D plasmid as a
template (this report). The PCR fragments were separated by
electrophoresis in agarose gel and extracted from the gel, and DNA was
cleaned using a Qiagen gel extraction kit and labeled with
32P using a random-prime labeling kit (Roche Molecular
Biochemicals) according to the manufacturer's protocols. The following
cDNA libraries were screened: human craniofacial (constructed from mRNA derived from the craniofacial region of human embryos ranging from 42- to 53-day gestation (36), mouse embryonic carcinoma (Stratagene), and mouse 15-day embryo (Novagene). The hybridization, washing, exposure, identification of the positive clones, excision, and
sequencing procedures were performed as previously described (4). The
exon-intron boundaries were identified by comparison of the identified
cDNA and the PITX2 genomic sequence. By using the 266-bp
homeobox sequence of the PITX2 as a probe, we identified multiple positive clones that can be divided into seven groups: sequences of PITX2 isoform A, PITX2
isoform B, PITX2 isoform C, PITX2 isoform D, partial PITX2
sequences that can be attributed to any isoform, and various sequences
belonging to either the PITX1 or PITX3
genes. The PITX2 A-C isoforms were described before (4, 6, 9, 21). The PITX2D isoform was only identified from
the human craniofacial library: two independent clones were isolated
from the 3 × 106 clones examined. The
PITX2D sequence consists of three exons: the first exon (178 bp), which was found to be located 230-bp upstream of the first exon of
the PITX2C isoform as it was identified from the human
craniofacial library; the second exon (77 bp) representing a partial
sequence of the PITX2 exon 5 lacking 129 of its
5'-nucleotides; and the third exon (1258 bp) that is equivalent to the
PITX2 exon 6 (Fig. 1). By
searching GenBankTM, we identified that the first exon of
the PITX2D isoform was found to be a part of the first exon
of the PITX2C isoform in two independent submissions: IMAGE
3937807 clone isolated from the lung library and ARP1C
(PITX2C) cDNA. Sequences at the exon/intron junctions
for the PITX2D were identified for the 5'-splice
site, GGGCTGCCGC/gt, and for the 3'-splice site,
cactttcc/AGAGGAACAGC. It is notable that the nucleotides at
positions 1 and 2 of the 3'-splice site (CC) do not correspond with
the conserved sequence identified as AG. The PITX2D isoform is
predicted to encode the 205-amino acid protein with the initiation
codon for methionine (ATG) located at the beginning of the second
helix sequence of the homeobox. Additional screening of the above
described libraries with the fragment containing the first exon
sequence of the PITX2D isoform failed to identify any clones from the
mouse cDNA libraries as well as any additional clones from the
human craniofacial cDNA library.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 1.
PITX2 major isoforms found in humans.
A, genomic organization of the PITX2 gene;
intron sizes are shown on the top, and exon sizes are at the
bottom; exons are numbered. B, the protein
structure is shown with the location of the homeodomain (HD)
and 14-amino acid conserved OAR domain. Checkered and
stippled boxes denote the differences in the N-terminal
region of the isoforms. The exons that code for the respective proteins
are shown below each isoform. PITX2C and PITX2D RNA is
transcribed using an internal promoter shown as a striped
box flanking exon 4.
|
|
Expression and Reporter Constructs--
Expression plasmids
containing the cytomegalovirus (CMV) promoter linked to the PITX2 DNA
were constructed in pcDNA 3.1 MycHisC (Invitrogen) (35).
Constructions of the Prolactin, Dlx2, and PLOD1 promoter plasmids have been previously described (3, 30, 31). All constructs were confirmed by DNA sequencing. A CMV
-galactosidase reporter plasmid (CLONTECH) was
co-transfected in all experiments as a control for transfection efficiency.
Cell Culture, Transient Transfections, Luciferase, and
-Galactosidase Assays--
CHO, HeLa, and LS-8 cells were cultured
in Dulbecco's modified Eagle's medium supplemented with 5% fetal
bovine serum and penicillin/streptomycin in 60-mm dishes and
transfected by electroporation. CHO, HeLa, and LS-8 cells were mixed
with 2.5 µg of expression plasmids, 5 µg of reporter plasmid, and
0.5 µg of CMV -galactosidase plasmid plated in 60-mm culture
dishes and fed with 5% fetal bovine serum and Dulbecco's modified
Eagle's medium. Electroporation of CHO cells was performed at 360 V
and 950 microfarads (Bio-Rad), and electroporation of HeLa cells was at
220 V and 950 microfarads. The cells were fed 24 h prior to
transfection. LS-8 cells were transfected by electroporation as
previously described (31). Transfected cells were incubated for 24 h then lysed and assayed for reporter activities and protein content by
Bradford assay (Bio-Rad). Luciferase was measured using reagents from
Promega. -Galactosidase was measured using the Galacto-Light Plus
reagents (Tropix Inc.). All luciferase activities were normalized to
-galactosidase activity. Expression of transiently expressed PITX2
proteins has been previously demonstrated (35).
 |
RESULTS |
PITX2 Isoforms Differentially Regulate the Dlx2, PLOD1, and
Prolactin Promoters--
To investigate the transcriptional activities
of the three major PITX2 isoforms, we used three different naturally
occurring promoters linked to the luciferase gene and assayed their
activity in three cell lines representing different tissues. We have
identified the only downstream targets of PITX2 outside of the
pituitary, and we compared the levels of PITX2 activation of these
promoters to the pituitary-specific Prolactin promoter. We
have previously shown that the PITX2A isoform can activate all three
promoters (30, 31, 35). We compared the activities of the PITX2 A, B,
and C isoforms using the full-length Dlx2-3276 and minimal Dlx2-200 promoters in CHO cells (Fig.
2A). PITX2A activates the Dlx2-3276 promoter at 30-fold, PITX2C at 22-fold, but
surprisingly PITX2B demonstrates only 2- to 3-fold activation of this
promoter compared with empty expression vector transfected as a control (Fig. 2B). Each isoform has limited activity when
transfected with the Dlx2-200 minimal promoter, which we use as a
control to demonstrate specific PITX2 activity. The result with PITX2B was surprising because all isoforms contain identical homeodomain and
C-terminal regions (Fig. 1). We and others (25, 29, 35) have shown that
the PITX2 C-terminal region contains a transcriptional activation
domain. Thus, this was an unexpected result and is probably due to the
presence of different PITX2 N-terminal sequences. Another explanation
for this result would include reduced expression or stability of PITX2B
in our transfected CHO cells. To address this we analyzed our
transfected CHO lysates for PITX2 protein expression and found equal
expression of all isoforms (Fig. 2C). Thus, these results
suggest that the N-terminal region of PITX2B may negatively regulate
its transcriptional activity in CHO cells using the Dlx2
promoter.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 2.
PITX2 isoform activation of the Dlx2 promoter
in CHO cells. A, schematic of the Dlx2
promoter constructs used in transient transfection assays showing the
location of bicoid and bicoid-like DNA elements;
Bcd, bicoid and bicoid-like sequences.
B, CHO cells were transfected with either the Dlx2-3276- or
Dlx2-200 luciferase reporter genes (5 µg). The cells were
co-transfected with the CMV-PITX2 isoform expression plasmids or the
CMV plasmid without PITX2 ( ) (2.5 µg). To control for transfection
efficiency, all transfections included the SV-40 -galactosidase
reporter (0.5 µg). Cells were incubated for 24 h then assayed
for luciferase and -galactosidase activities. The activities are
shown as mean -fold activation compared with the Dlx2
promoter plasmids without PITX2 expression and normalized to
-galactosidase activity (±S.E. from ten independent experiments for
panel B). The mean Dlx2 promoter luciferase
activity with PITX2 expression was about 100,000 light units per 15 µg of protein, and the -galactosidase activity was about 70,000 light units per 15 µg of protein. C, Western blot of
transfected CHO cell lysates using the PITX2 antibody. CHO cell lysates
from transfection experiments in panel B (10 µg) were
tested for PITX2 isoform expression. As a control, 500 ng of
bacterial-expressed PITX2A was used to show the correct migration of
the transient-expressed PITX2 isoform proteins. CHO cells
co-transfected with the Dlx2 promoter construct and empty
expression vector were used as the mock control.
|
|
We next asked if these PITX2 isoforms would differentially regulate the
PLOD1 promoter. Two PLOD1 promoter constructs
were made and linked to the luciferase gene (Fig.
3A). PITX2A activated the
full-length PLOD1-261 promoter at 10-fold, whereas PITX2C revealed
increased activity at 17-fold and PITX2B demonstrated only 2-fold
activation in transfected CHO cells, compared with empty vector
transfection (Fig. 3B). Although these results again reveal
that PITX2B has little activity in contrast to experiments with the
Dlx2 promoter, PITX2C is more active than PITX2A when assayed in the same cell line (p < 0.05). These
results indicate that the activities of the PITX2 isoforms, though
subtle, are promoter-dependent.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
PITX2 isoform activation of the PLOD1
promoter in CHO cells. A, schematic of the
PLOD1 promoter constructs used in transient transfection
assays showing the location of bicoid and
bicoid-like DNA elements. B, CHO cells were
transfected with either the PLOD1-261 or PLOD1-2561 luciferase
reporter genes (5 µg). The cells were co-transfected with the
CMV-PITX2 isoform expression plasmids or the CMV plasmid without PITX2
( ) (2.5 µg). All transfection assays were performed as described in
Fig. 2. The activities are shown as mean -fold activation compared with
the PLOD1 promoter plasmids without PITX2 expression and
normalized to -galactosidase activity (±S.E. from nine independent
experiments).
|
|
To further analyze the differences in PITX2 isoform activities, we have
used the pituitary-specific Prolactin promoter. It has been
previously reported that the three major PITX2 isoforms, including
PITX2B, all activated several pituitary promoters at similar levels
(29, 37). We co-transfected the naturally occurring Prolactin promoter with the PITX2 isoforms and found that
PITX2B gave the greatest activation with this promoter in CHO cells
(Fig. 4). PITX2A and PITX2C activated the
Prolactin promoter at slightly less levels. Thus, our data
agree with other investigators using the Prolactin promoter.
Altogether these results demonstrate that the PITX2 A, B, and C
isoforms have different transcriptional activities that are
promoter-dependent. However, PITX2B is only active using
the Prolactin promoter in CHO cells.

View larger version (6K):
[in this window]
[in a new window]
|
Fig. 4.
PITX2 isoform activation of the
Prolactin promoter in CHO cells. CHO cells were
transfected with the prolactin 2.5-luciferase reporter plasmid and
co-transfected with the CMV-PITX2 isoform expression plasmids or the
parental CMV plasmid without PITX2 ( ). All transfection assays were
performed as described in Fig. 2. The activities are shown as mean
-fold activation compared with the Prolactin promoter
plasmids without PITX2 expression and normalized to -galactosidase
activity (±S.E. from eight independent experiments).
|
|
DNA Binding Activities of the PITX2 Isoforms--
A possible
explanation for the differential transcriptional regulation would be
due to differences in DNA binding activities by the isoforms. We next
asked if these PITX2 isoforms bound the Dlx2
bicoid DNA element (5'-TAATCC-3') at similar activities. We
expected that they would, because they all contain identical homeodomains; however, the different N termini could influence their
binding activities. We have previously reported that the PITX2A
C-terminal tail can interact with the N terminus to modulate its DNA
binding activity (35, 37). Therefore, we speculated that this
interaction could be either disrupted or enhanced depending on the
relative structure of the N terminus. However, we demonstrate that each
isoform binds the Dlx2 bicoid element with
similar activities and all form homodimers (Fig.
5). We assayed increasing protein concentrations from 80 to 240 ng for each isoform (Fig. 5). Thus, the
lack of PITX2B activity using the Dlx2 and PLOD1
promoters was not due to a disruption of its DNA binding activity,
because both promoters contain multiple bicoid elements.

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 5.
PITX2 isoforms have similar binding
activities. PITX2 proteins (80, 160, and 240 ng) were incubated
with the Dlx2 bicoid consensus sequence (TAATCC) as the
radioactive probe. The EMSA experiments were analyzed in 8% native
polyacrylamide gels. The free and bound forms of DNA were quantitated
using the Molecular Dynamics Storm PhosphorImager (Amersham
Biosciences). The free probe, bound, and dimer complexes are
indicated.
|
|
Cell-specific Regulation of PITX2 Isoform Transcriptional
Activity--
Because all three major PITX2 isoforms contain different
N-terminal amino acid sequences, we asked if cellular factors might influence their activities. As we discussed in the introduction the
PITX2 isoforms are expressed in distinct and overlapping domains during
human, frog, mouse, zebrafish, and chick development. We reasoned that
these isoforms might have different activities in cell lines derived
from different tissues and vertebrate species, due to PITX2 interacting
factors. Transfection of HeLa cells with the Dlx2 promoter
revealed changes in PITX2 isoform activities compared with CHO
transfections presented in Fig. 2B. In HeLa cells PITX2C was
more active than PITX2A: compare the 5-fold activation of Dlx2-3276
for PITX2C to the 3-fold activation for PITX2A (p < 0.05) (Fig. 6). In CHO cells PITX2A was
more active than PITX2C using the Dlx2 promoter
(p < 0.05). However, PITX2B remained inactive in HeLa
cells. These data clearly demonstrate a difference in PITX2 isoform
activity based on the transfected cell line. We further analyzed this
response in a tooth epithelial cell line, LS-8, which we have
previously shown reduces the activity of the Dlx2 promoter
when co-transfected with PITX2A, compared with CHO cells (31). In this
cell line the activities of all three major PITX2 isoforms were
similar, albeit with low activation as we have previously reported
(Fig. 7). LS-8 cells endogenously express Msx2, which can antagonize PITX2 activation of the Dlx2
promoter (31). Furthermore, we have shown that the LS-8 cell line
contains factors that complex with PITX2A to presumably regulate its
activity. The reduced PITX2 activation of the Dlx2 promoter
in LS-8 cells is currently under investigation. Reverse
transcription-PCR experiments have identified the expression of
Pitx2a and Pitx2c but not Pitx2b in
this cell line (31). Altogether, these data demonstrate a cell-specific
regulation of PITX2 isoform transcriptional activity.

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 6.
PITX2 isoform activation of the
Dlx2 promoter in HeLa cells. HeLa cells were
transfected with either the Dlx2-3276- or Dlx2-200 luciferase
reporter genes (5 µg). The cells were co-transfected with the
CMV-PITX2 isoform expression plasmids or the CMV plasmid without PITX2
( ) (2.5 µg). To control for transfection efficiency, all
transfections included the SV-40 -galactosidase reporter (0.5 µg).
Cells were incubated for 24 h then assayed for luciferase and
-galactosidase activities. The activities are shown as mean -fold
activation compared with the Dlx2 promoter plasmids without
PITX2 expression and normalized to -galactosidase activity (±S.E.
from eight independent experiments).
|
|

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 7.
PITX2 isoform activation of the
Dlx2 promoter in the LS-8 tooth epithelial cell
line. LS-8 cells were transfected with either the Dlx2-3325- or
Dlx2-250 luciferase reporter genes. The cells were co-transfected with
the CMV-PITX2 isoform expression plasmids or the CMV plasmid without
PITX2 ( ). To control for transfection efficiency, all transfections
included the CMV -galactosidase reporter. Cells were incubated for
24 h then assayed for luciferase and -galactosidase activities.
The activities are shown as mean -fold activation compared with the
Dlx2 promoters without PITX2 expression and normalized to
-galactosidase activity (±S.E. from six independent experiments).
The mean Dlx2-3325 luciferase activity with PITX2 expression was about
5,000 light units per 15 µg of protein, and the -galactosidase
activity was about 40,000 light units per 15 µg of protein.
|
|
Transcriptional Synergism by PITX2 Isoforms--
PITX2 isoforms
are co-expressed in different combinations during vertebrate
development. All three major Pitx2 isoforms are expressed in
the pituitary and craniofacial region, whereas other organs and tissues
express combinations of the isoforms that can be
species-dependent. To examine the effect of these isoforms acting together to regulate gene expression, we transfected CHO cells
with combinations of PITX2A, 2B, and 2C. PITX2A activated the
Dlx2 promoter at 30-fold and PITX2B at 2-fold compared with empty vector, but surprisingly co-transfection of both yielded a
synergistic 67-fold activation of the Dlx2 promoter (Fig.
8). Co-transfection of PITX2C and PITX2B
also revealed a synergistic 63-fold activation, whereas co-transfection
of PITX2A and PITX2C resulted in only an additive effect (Fig. 8).
These data suggest that PITX2B can interact with PITX2A and 2C to
increase their transcriptional activities.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 8.
Transcriptional synergism of PITX2 isoforms
in CHO cells. A, CHO cells were transfected with either
the Dlx2-3276- or Dlx2-200 luciferase reporter genes (5 µg). The
cells were co-transfected with combinations of the CMV-PITX2 isoform
expression plasmids or the CMV plasmid without PITX2 ( ) (2.5 µg
each). To control for transfection efficiency, all transfections
included the SV-40 -galactosidase reporter (0.5 µg). Cells were
incubated for 24 h then assayed for luciferase and
-galactosidase activities. The activities are shown as mean -fold
activation compared with the Dlx2 promoter plasmids without
PITX2 expression and normalized to -galactosidase activity (±S.E.
from ten independent experiments).
|
|
To determine if CHO cells provided factors that enhanced the PITX2B
interactions and transcriptional activity, we also co-transfected HeLa
cells. In HeLa cells we observed similar results compared with
transfected CHO cells. PITX2A activated the Dlx2 promoter at
3-fold, whereas PITX2B was inactive; however, co-transfection of both
PITX2A and 2B yielded a 7-fold activation (Fig.
9). Co-transfection of PITX2B and PITX2C
activated the Dlx2 promoter in HeLa cells at 7-fold compared
with empty vector control transfection (Fig. 9). However,
co-transfection of PITX2A and PITX2C resulted in an additive effect
similar to CHO cells (Fig. 9).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 9.
Transcriptional synergism of PITX2 isoforms
in HeLa cells. HeLa cells were transfected as described in Fig.
8.
|
|
Interestingly, we observe less dramatic synergistic effects through
PITX2 isoform interactions using the Prolactin promoter in
CHO cells. Co-transfection of PITX2A and PITX2B resulted in a 15-fold
activation, PITX2A and PITX2C co-transfection resulted in a 16-fold
activation, and PITX2B and PITX2C resulted in a 21-fold activation
(Fig. 10). Surprisingly, with the
Prolactin promoter, all three isoforms can synergize with
each other, whereas with the Dlx2 and PLOD1
promoters co-transfection of PITX2A and PITX2C resulted in additive
activation (data not shown for PLOD1). Clearly, these
isoforms can interact and significantly increase promoter activity.
These data, when taken together, reveal a mechanism for the
combinatorial role these isoforms can play when expressed in the same
tissues during development. This type of mechanism would rapidly
activate genes required for normal development, and the control of
PITX2 isoform expression would work to tightly control gene expression.
Furthermore, although PITX2B appears inactive by itself, we demonstrate
a critical role for this isoform in activation of the Dlx2
and PLOD1 genes.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 10.
Transcriptional synergism of PITX2 isoforms
using the Prolactin promoter in CHO cells. CHO
cells were transfected as described in Fig. 4, using combinations of
the PITX2 isoform expression plasmids.
|
|
PITX2 Isoforms Heterodimerize--
Because we have shown
transcriptional synergy between PITX2A and 2C with PITX2B, we next
asked if this was due to physical interactions between these isoforms.
To address this question we used EMSAs to determine if heterodimers
were formed when combinations of the isoforms were mixed together and
allowed to bind to the Dlx2 bicoid probe. We have
previously demonstrated, using GST-PITX2 pull-down assays, that PITX2
isoforms can physically interact (31). When PITX2A and 2B were mixed in
equal amounts (80 ng) we observed an increase in DNA binding through
the formation of heterodimers and little increase in monomer binding
(Fig. 11). Quantitation of the gels
revealed that most of the PITX2B bound as a heterodimer complex with
PITX2A. This is visualized as a large slower migrating complex above
the PITX2A monomer band (Fig. 11). Interestingly, mixing equal amounts
of PITX2A and 2C resulted in a slight increase in heterodimer formation
however; the increase in overall binding resulted from an increase in
each protein binding as a monomer (Fig. 11). This can be seen by two
separate faster migrating bands, which run at the same position as each
separate monomer protein. Mixing equal amounts of PITX2C and PITX2B
resulted in an increase in heterodimer formation (Fig. 11). Overall
these results reveal that the PITX2B isoform appears to facilitate
dimerization with PITX2A and PITX2C. These data suggest that the
transcriptional synergism observed between PITX2A and PITX2C with
PITX2B occurs through the ability of the PITX2B isoform to physically
interact with the other two isoforms.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 11.
PITX2B forms dimers with the other PITX2
isoforms. PITX2 proteins (80 ng) were incubated either separately
or in combinations with the Dlx2 bicoid consensus sequence
(TAATCC) as the radioactive probe. The EMSA experiments were analyzed
in 8% native polyacrylamide gels. The free and bound forms of DNA were
quantitated using the Molecular Dynamics Storm PhosphorImager (Amersham
Biosciences). The free probe, bound, and dimer complexes are
indicated.
|
|
The PITX2D Isoform Inhibits the Transcriptional Activity of PITX2A
and PITX2C--
We have identified a new PITX2 isoform from
a human craniofacial library. It is made by alternative splicing of a
transcript produced from the internal promoter located in intron 3, which also produces the PITX2C isoform (Fig. 1).
PITX2D results from splicing of exon 4a to a cryptic
3'-splice site in exon 5, which produces a truncated homeodomain and
complete C-terminal tail. We have shown that this isoform does not bind
to DNA as expected, because it does not contain a functional
homeodomain (Fig. 5). However, because it is expressed with the other
isoforms, we asked if it had a functional activity with respect to the
other isoforms. CHO cells were co-transfected with the Dlx2
promoter and PITX2 expression plasmids. As expected, PITX2D has no
transcriptional activity when transfected with the Dlx2
promoter (Fig. 12A).
However, when co-transfected with PITX2A, PITX2D caused a 3-fold
reduction in PITX2A transcriptional activity of the Dlx2-3276-luc
promoter, from 30- to ~10-fold in CHO cells (Fig. 12A). A
2-fold reduction of PITX2C transcriptional activity was observed when
co-transfected with PITX2D, from 25- to 12-fold (Fig. 12A).
PITX2D had no effect on the transcriptional activity of PITX2B, which
we have shown is not active with this promoter. Co-transfection of the
PITX2 isoforms with the minimal Dlx2-200-luc plasmid revealed little activation, and PITX2D only minimally inhibited this activation (Fig.
12A). These data reveal that PITX2D can negatively regulate the transcriptional activities of PITX2A and PITX2C isoforms.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 12.
PITX2D suppresses Dlx2
promoter activation by the other PITX2 isoforms. CHO cells
were transfected as in Fig. 2 except that PITX2D (2.5 µg) was
co-transfected where indicated with the other PITX2 isoform plasmids.
B, Western blot of transfected CHO cell lysates using the
PITX2 antibody. CHO cell lysates from transfection experiments in
panel A (10 and 20 µg) were tested for PITX2A expression.
As a control, 1 µg of bacterial expressed PITX2A was used to show the
correct migration of the transient expressed PITX2A protein. Our PITX2
antibody will not recognize the PITX2D isoform, because the antibody
epitope flanks the homeodomain and lies in the N-terminal region shared
by the other three PITX2 isoforms (28, 31). This epitope is missing in
the PITX2D isoform. CHO cells co-transfected with the Dlx2
promoter construct and empty expression vector were used as the mock
control.
|
|
A possible explanation for these results could involve a mechanism
where the PITX2D RNA inhibits the translation of the other PITX2
isoforms in CHO cells. We performed a Western blot of transfected CHO
cell lysates to determine if PITX2A expression and protein stability
were affected by PITX2D. We assayed two concentrations of CHO lysates
and found that co-expression of PITX2D with PITX2A had no effect on
PITX2A protein expression or stability (Fig. 12B). We also
found that PITX2C protein expression was unaffected by co-expression of
PITX2D (data not shown). Our PITX2 antibody recognizes an N-terminal
epitope shared by PITX2A, B, and C isoforms however, it will not
recognize PITX2D because the epitope is lost. All of our PITX2
expression plasmids contain a C-terminal Myc tag that allows us to
observe PITX2D expression using the Myc antibody (data not shown).
These results suggest that factors specific for CHO cells might
interact with PITX2D to facilitate its repression of PITX2A and 2C
transcriptional activity. To address this possibility we transfected
HeLa cells and observed similar repression of PITX2A and 2C activity
using the Dlx2-3276-luc reporter plasmid by PITX2D as seen in CHO
cells (Fig. 13). Thus, this repressive
effect of PITX2D does not appear to be due to specific factors
associated with a specific cell line. The repressive effects by PITX2D
were observed with other promoter constructs, including the
PLOD1 and Prolactin promoters demonstrating that
this effect is not restricted to a specific promoter (data not
shown).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 13.
PITX2D suppresses Dlx2
promoter activation in HeLa cells. HeLa cells were
transfected as in Fig. 6 except that PITX2D (2.5 µg) was
co-transfected were indicated with the other PITX2 isoform
plasmids.
|
|
PITX2D Physically Interacts with PITX2A and PITX2C
Isoforms--
Our transfection results indicate that PITX2D could
physically interact with the other PITX2 isoforms to attenuate their
activity. We used GST-PITX2D pull-down assays to determine if PITX2A
and PITX2C isoforms could interact with PITX2D. GST-PITX2D was
immobilized to Sepharose 4B beads (Amersham Biosciences) and incubated
with bacteria-expressed and -purified PITX2 isoforms. As a control the
purified PITX2 isoform proteins were also incubated with GST beads.
PITX2A and PITX2C were able to bind to immobilized GST-PITX2D (Fig.
14). As a control we show that GST
beads alone did not bind PITX2A or C (Fig. 14). These data clearly
demonstrate that the PITX2D isoform can physically interact with the
other PITX2 isoforms. These experiments corroborate our previous
experiments demonstrating that PITX2 isoforms interact through their
C-terminal tails (31). Because all PITX2 isoforms contain identical
C-terminal tails, our data demonstrate that each isoform has the
capability to interact with other isoforms. Another explanation for the
suppression of PITX2A and PITX2C activity by PITX2D might be due to the
inability of a PITX2A/2D or PITX2C/2D complex to bind DNA. We performed EMSAs where we mixed PITX2A and PITX2C with PITX2D and found neither a
loss of binding or increased PITX2A or PITX2C binding activity (data
not shown). Clearly, the easiest explanation is that PITX2D binds
factors that are essential for PITX2 activity, thereby sequestering that factor from interacting with PITX2 isoforms. Although this is a
possibility, we speculate that PITX2D directly binds to PITX2A and
PITX2C to inhibit their activity. This mechanism is analogous to our
previous report demonstrating that the C-terminal 39-amino acid peptide
can also inhibit the transcriptional activity of PITX2A (35).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 14.
PITX2D directly interacts with PITX2A and
PITX2C. GST-PITX2D pull-down assay with bacterial-expressed and
-purified PITX2A and PITX2C proteins. The PITX2A and PITX22C isoforms
bind to PITX2D demonstrating that PITX2D can physically interact with
the other isoforms. The bound isoforms were detected by Western blot
using the PITX2 antibody. As a control, GST beads were incubated with
purified PITX2A and PITX2C proteins to demonstrate the specificity of
binding to PITX2D.
|
|
 |
DISCUSSION |
Gene expression can be regulated by alternatively spliced
transcription factors. Alternative splicing of transcription factors provides a mechanism for the fine-tuning of gene expression during development. Three major PITX2 isoforms have been isolated and shown to
differentially regulate organogenesis. However, the molecular mechanism
for this development preference of the different PITX2 isoforms was
unknown. We have been studying the mechanism of PITX2 transcriptional
regulation and have recently identified several genes that are
regulated by PITX2 (28, 31, 35). The results from the present study
reveal a promoter- and cell-dependent activation by the
three major PITX2 isoforms. Our recent identification of a fourth minor
PITX2 isoform expressed in humans adds another level of regulation to
the transcriptional activity of PITX2.
In the brain, craniofacial region, and pituitary, which express all
three major PITX2 isoforms, the interactions between PITX2 isoforms
provide a mechanism to tightly regulate gene expression controlled by
PITX2. Our research provides several mechanisms by which PITX2 isoforms
may interact to both activate and repress gene expression. We have
shown in this report and previously (31, 35) that the PITX2 isoforms
can heterodimerize. Furthermore, we have shown that PITX2A can
synergize with Pit-1 to activate the Prolactin promoter (3,
35). All of the major PITX2 isoforms can interact with Pit-1 to
synergistically activate the Prolactin promoter
(29).2 Our results
demonstrate that the PITX2 isoforms interact to specifically regulate
Prolactin gene expression. We have provided new insights into pituitary development by demonstrating that the three major PITX2
isoforms interact to significantly up-regulate Prolactin expression. Thus, the levels and combinations of PITX2 isoform expression contribute to the dosage-response model proposed for pituitary and other organ development (17, 24).
Interestingly, using the Dlx2 promoter whose gene product is
expressed during craniofacial and brain development, we find that PITX2A is more active than PITX2C whereas PITX2B has minimal activity. However, PITX2B, when co-transfected with PITX2A or PITX2C
isoforms, results in synergistic activation of the Dlx2 promoter. It has been reported that all three major PITX2 isoforms are
expressed in the brain and craniofacial region (37). Thus, even though
a different promoter regulates PITX2C expression its level
of expression is similar to PITX2A and 2B in the brain. Therefore, the
location of PITX2 isoform expression in regions of the developing
embryo could have important effects on PITX2 target gene expression
such as Dlx2. During embryogenesis, we speculate
based on our research that the combination and levels of PITX2 isoform
expression will greatly influence Dlx2 gene expression. We
demonstrate this type of regulation by using different cell lines,
which reveal differences in PITX2 isoform activities. PITX2A activates
the Dlx2 promoter more strongly than PITX2C in CHO cells whereas, PITX2C activates the Dlx2 promoter more strongly in
HeLa cells compared with PITX2A. However, PITX2B is inactive in both cell lines. Furthermore, we use a tooth epithelial cell line to assay
PITX2 isoform activities and observe a different ratio of PITX2 isoform
transcriptional activities. These data reveal a preference for PITX2
isoform transcriptional activity based on the cells used in our
transfection experiments. We propose that PITX2 isoform transcriptional
activity will be similarly different in tissues of the developing embryo.
In contrast to Dlx2 and Prolactin expression by
PITX2 isoforms, the PLOD1 promoter is activated more
strongly by PITX2C than PITX2A in CHO cells. Similar to Dlx2
the PLOD1 promoter is not activated by PITX2B. However, the
Dlx2 and PLOD1 promoters are activated
synergistically by the combination of PITX2A/2B and PITX2C/2B (Figs. 8
and 9).2 Interestingly, PLOD1 has been shown to
be expressed in the heart, and because PITX2C has been reported to be
the major isoform expressed in the heart our results corroborate the
function of PITX2C in heart development. Furthermore, our laboratory
has recently identified a heart-specific gene that is regulated by
PITX2 isoforms, however, only PITX2C can synergistically activate this
promoter in the presence of another heart-specific transcription
factor.3 Through the use of
three naturally occurring promoters we are able to demonstrate specific
differences in PITX2 isoform activities. We have shown that the
activities of the major PITX2 isoforms are dependent on the specific
promoter they activate and the cells in which they are expressed. Our
research provides the first functional mechanism for differential gene
expression by PITX2A, 2B, and 2C isoforms. It has been shown that other
transcription factor isoforms can differentially regulate gene
expression. The Pax-5 gene produces four isoforms as a
result of alternative splicing, which can act to either positively or
negatively regulate gene expression (38). Interestingly, an alternative
form of Pax5, termed Pax5e, does not bind DNA but causes an increase in
Pax5a activity. Thus, there is precedence for alternatively
spliced transcription factors that do not bind DNA but can exert a
regulatory effect on the other isoforms. However, our data reveal a
negative regulatory mechanism for the PITX2D isoform. The
Pit-1 transcription factor gene produces alternatively
spliced products that regulate Prolactin gene expression
(39).
Because the major PITX2 isoforms only differ in their N termini, we
speculate that the N terminus must play a role in the differential
transcriptional activities of these isoforms. However, we have
shown that each isoform binds DNA similarly, thus, the N
terminus must interact with tissue- and/or cell-specific factors to
regulate their activities. Our data indicate that this occurs because
we observed transcriptional activation differences in several cell
lines. To address the functional properties of the different N termini
we have co-transfected each N-terminal-specific peptide with the PITX2
isoforms (data not shown). Our rationale was that if the N termini were
binding specific factors then expression of the N-terminal peptides
would sequester cellular factors by binding them and thus allow for
differential regulation by the wild-type isoforms. Interestingly, when
we co-transfected the PITX2A isoform with the PITX2A and PITX2B
N-terminal peptides, we observed a 2-fold increase in PITX2A
transcriptional activity.2 These data suggest that the N
termini of the PITX2 isoforms may be binding factors, which regulate
their activities. However, co-transfection of the 2C N-terminal peptide
had no effect on PITX2A activity. We did not present these results in
this report because they are difficult to interpret. However, they do
provide clues that the N terminus of each PITX2 isoform may bind
cell-specific factors that regulate their activities.
Functions of PITX2D--
Our transfection data clearly demonstrate
that isoform PITX2D has the ability to act as a transcriptional
suppressor. We demonstrated that PITX2D inhibits PITX2A and 2C
activation of the Dlx2 promoter. Furthermore, this
inhibition occurs in CHO, HeLa, and LS-8 cells, demonstrating that it
was not cell-specific. We also observe this inhibitory effect with the
PLOD1 and Prolactin promoters.2
PITX2D has a truncated homeodomain, which is derived from the use of a
cryptic 3'-splice site. This isoform appears to be produced as a result
of aberrant splicing in humans. We isolated this isoform from a human
craniofacial library, and the specific tissue or organ distribution of
this isoform has not yet been determined. However, we have repeatedly
seen this isoform in human craniofacial libraries, and we speculate
that it may have important functions in regulating PITX2
transcriptional activity in humans. PITX2D does not bind DNA, and we
have shown that it does not inhibit the expression of PITX2 isoforms in
the transfected cell lines. However, it does physically interact with
the major PITX2 isoform proteins, which appear to be the mechanism by
which it inhibits the activity of the other isoforms. Interestingly,
this isoform acts in a very similar manner to that of our
previously reported PITX2 C-terminal 39-amino acid peptide, which acts
to inhibit PITX2A transcriptional activity in transfected cells (35).
In that report we demonstrated that the PITX2 C39 peptide bound to PITX2 to inhibit its transcriptional activity and, similarly, in this
report we demonstrate that PITX2D also binds PITX2A and PITX2C isoforms.
The mechanism of this suppressive effect is currently unknown, and we
are investigating its action. But, interestingly, we and others (25,
29, 35) have reported the existence of a transactivation domain in the
C terminus of PITX2. Thus, if the PITX2D protein forms a heterodimer
with the other isoforms, it should be able to activate the promoters in
our transfection assays because it contains the C-terminal
transactivation domain. Because mixing PITX2D with each PITX2 isoform
does not inhibit their DNA binding activity (data not shown), then
suppression of PITX2A and PITX2C transcriptional activity is not caused
by a loss of DNA binding activity. One explanation for the suppressive
effect would involve PITX2D-binding cellular factors required for PITX2 activity. We and others (35, 40) have shown that the C-terminal region
of PITX2 is important for protein-protein interaction and that it binds
cellular factors. Thus, PITX2D may act to suppress the activity of the
other PITX2 isoforms by "soaking up" factors that normally bind
to PITX2. We have titrated PITX2D DNA concentrations in our
transfection experiments and have not observe a corresponding decrease
in PITX2 activation upon increased PITX2D DNA
concentrations.2 Thus, it appears unlikely that PITX2D
binds a factor essential for PITX2 activity. We are currently
investigating the mechanism of this novel PITX2 isoform.
Developmentally, it does provide an interesting mechanism for the
regulation and fine-tuning of PITX2 transcriptional activity, which
appears to be required for the normal morphogenesis of several organs.
In summary, our studies provide evidence that PITX2 isoforms
differentially activate genes involved in development. We provide a
molecular basis for organ/tissue development by PITX2 isoforms, where
the expression of PITX2 isoforms can greatly influence gene expression.
Furthermore, we provide evidence for the regulation of PITX2 isoform
transcriptional activity in a cell-dependent manner.
Lastly, we demonstrate a new mechanism for the regulation of PITX2
transcriptional activation through the action of a novel PITX2 isoform.
 |
ACKNOWLEDGEMENTS |
We thank John Hall and Crystal (Zoe) Hansen
for excellent technical assistance and Drs. Jeffrey C. Murray and
Andrew F. Russo (University of Iowa) for reagents and helpful
discussions. We also thank Drs. Paul Sharpe and Bethan Thomas (King's
College, University of London) for the Dlx2 promoter plasmid.
 |
FOOTNOTES |
*
This work was supported by Grant 1-RO1-DE13941 from the
NIDCR, National Institutes of Health (to B. A. A.) and by the Fight For Sight Research Division of Prevent Blindness America (Postdoctoral Grant PD99018 to T. A. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Biological Sciences, The University of Tulsa, 600 S. College Ave.,
Tulsa, OK 74104-3189. Tel.: 918-631-3328; Fax: 918-631-2762; E-mail: brad-amendt@utulsa.edu.
Published, JBC Papers in Press, April 10, 2002, DOI 10.1074/jbc.M201737200
2
C. J. Cox, H. M. Espinoza, B. McWilliams, K. Chappell, L. Morton, T. A. Hjalt, E. V. Semina, and B. A. Amendt, unpublished observations.
3
C. J. Cox, H. M. Espinoza, B. McWilliams, K. Chappell, L. Morton, T. A. Hjalt, E. V. Semina, and B. A. Amendt, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
GST, glutathione
S-transferase;
EMSA, electrophoretic mobility shift assay;
CMV, cytomegalovirus;
CHO, Chinese hamster ovary cells.
 |
REFERENCES |
| 1.
|
Dubnau, J.,
and Struhl, G.
(1996)
Nature
379,
694-699[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Lamonerie, T.,
Tremblay, J. J.,
Lanctot, C.,
Therrien, M.,
Gauthier, Y.,
and Drouin, J.
(1996)
Genes Dev.
10,
1284-1295[Abstract/Free Full Text]
|
| 3.
|
Amendt, B. A.,
Sutherland, L. B.,
Semina, E.,
and Russo, A. F.
(1998)
J. Biol. Chem.
273,
20066-20072[Abstract/Free Full Text]
|
| 4.
|
Semina, E. V.,
Reiter, R.,
Leysens, N. J.,
Alward, L. M.,
Small, K. W.,
Datson, N. A.,
Siegel-Bartelt, J.,
Bierke-Nelson, D.,
Bitoun, P.,
Zabel, B. U.,
Carey, J. C.,
and Murray, J. C.
(1996)
Nat. Genet.
14,
392-399[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Amendt, B. A.,
Semina, E. V.,
and Alward, W. L. M.
(2000)
Cell. Mol. Life Sci.
57,
1652-1666[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Gage, P. J.,
and Camper, S. A.
(1997)
Hum. Mol. Genet.
6,
457-464[Abstract/Free Full Text]
|
| 7.
|
Mucchielli, M.,
Martinez, S.,
Pattyn, A.,
Goridis, C.,
and Brunet, J.
(1996)
Mol. Cell. Neurosci.
8,
258-271[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Kitamura, K.,
Miura, H.,
Yanazawa, M.,
Miyashita, T.,
and Kato, K.
(1997)
Mech. Dev.
67,
83-96[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Arakawa, H.,
Nakamura, T.,
Zhadanov, A. B.,
Fidanza, V.,
Yano, T.,
Bullrich, F.,
Shimizu, M.,
Blechman, J.,
Mazo, A.,
Canaani, E.,
and Croce, C. M.
(1998)
Proc. Natl. Acad. Sci.
95,
4573-4578[Abstract/Free Full Text]
|
| 10.
|
Campione, M.,
Steinbeisser, H.,
Schweickert, A.,
Deissler, K.,
van Bebber, F.,
Lowe, L. A.,
Nowotschin, S.,
Viebahn, C.,
Haffter, P.,
Kuehn, M. R.,
and Blum, M.
(1999)
Dev.
126,
1225-1234[Abstract]
|
| 11.
|
Yoshioka, H.,
Meno, C.,
Koshiba, K.,
Sugihara, M.,
Itoh, H.,
Ishimaru, Y.,
Inoue, T.,
Ohuchi, H.,
Semina, E. V.,
Murray, J. C.,
Hamada, H.,
and Noji, S.
(1998)
Cell
94,
299-305[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Semina, E. V.,
Reiter, R. S.,
and Murray, J. C.
(1997)
Hum. Mol. Genet.
6,
2109-2116[Abstract/Free Full Text]
|
| 13.
|
Logan, M.,
Pagan-Westphal, S. M.,
Smith, D. M.,
Paganessi, L.,
and Tabin, C. J.
(1998)
Cell
94,
307-317[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Piedra, M. E.,
Icardo, J. M.,
Albajar, M.,
Rodriguez-Rey, J. C.,
and Ros, M. A.
(1998)
Cell
94,
319-324[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Ryan, A. K.,
Blumberg, B.,
Rodriguez-Esteban, C.,
Yonei-Tamura, S.,
Tamura, K.,
Tsukui, T.,
de la Pena, J.,
Sabbagh, W.,
Greenwald, J.,
Choe, S.,
Norris, D. P.,
Robertson, E. J.,
Evans, R. M.,
Rosenfeld, M. G.,
and Belmonte, J. C. I.
(1998)
Nature
394,
545-551[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
St. Amand, T. R., Ra, J.,
Zhang, Y., Hu, Y.,
Baber, S. I.,
Qiu, M.,
and Chen, Y. P.
(1998)
Biochem. Biophys. Res. Commun.
247,
100-105[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Gage, P. J.,
Suh, H.,
and Camper, S. A.
(1999)
Development
126,
4643-4651[Abstract]
|
| 18.
|
Lu, M.,
Pressman, C.,
Dyer, R.,
Johnson, R. L.,
and Martin, J. F.
(1999)
Nature
401,
276-278[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Lin, C. R.,
Kioussi, C.,
O'Connell, S.,
Briata, P.,
Szeto, D.,
Liu, F.,
Izpisua-Belmonte, J. C.,
and Rosenfeld, M. G.
(1999)
Nature
401,
279-282[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Flomen, R. H.,
Gorman, P. A.,
Vatcheva, R.,
Groet, J.,
Barisic, I.,
Ligutic, I.,
Sheer, D.,
and Nizetic, D.
(1997)
J. Med. Genet.
34,
191-195[Abstract/Free Full Text]
|
| 21.
|
Gage, P. J.,
Suh, H.,
and Camper, S. A.
(1999)
Dev. Biol.
210,
234
|
| 22.
|
Kitamura, K.,
Miura, H.,
Miyagawa-Tomita, S.,
Yanazawa, M.,
Katoh-Fukui, Y.,
Suzuki, R.,
Ohuchi, H.,
Suehiro, A.,
Motegi, Y.,
Nakahara, Y.,
Kondo, S.,
and Yokoyama, M.
(1999)
Development
126,
5749-5758[Abstract]
|
| 23.
|
Essner, J. J.,
Branford, W. W.,
Zhang, J.,
and Yost, H. J.
(2000)
Development
127,
1081-1093[Abstract]
|
| 24.
|
Liu, C.,
Liu, W., Lu, M.,
Brown, N. A.,
and Martin, J. F.
(2001)
Dev.
128,
2039-2048[Abstract/Free Full Text]
|
| 25.
|
Yu, X., St.,
Amand, T. R.,
Wang, S., Li, G.,
Zhang, Y., Hu, Y.,
Nguyen, L.,
Qiu, M.,
and Chen, Y.
(2001)
Development
128,
1005-1013[Abstract]
|
| 26.
|
Schweickert, A.,
Campione, M.,
Steinbeisser, H.,
and Blum, M.
(2000)
Mech. Dev.
90,
41-51[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Mucchielli, M.-L.,
Mitsiadis, T. A.,
Raffo, S.,
Brunet, J.-F.,
Proust, J.-P.,
and Goridis, C.
(1997)
Dev. Biol.
189,
275-284[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Hjalt, T. A.,
Semina, E. V.,
Amendt, B. A.,
and Murray, J. C.
(2000)
Dev. Dyn.
218,
195-200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Tremblay, J. J.,
Goodyer, C. G.,
and Drouin, J.
(2000)
Neuroendocrinology
71,
277-286[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Hjalt, T. A.,
Amendt, B. A.,
and Murray, J. C.
(2001)
J. Cell Biol.
152,
545-552[Abstract/Free Full Text]
|
| 31.
|
Green, P. D.,
Hjalt, T. A.,
Kirk, D. E.,
Sutherland, L. B.,
Thomas, B. L.,
Sharpe, P. T.,
Snead, M. L.,
Murray, J. C.,
Russo, A. F.,
and Amendt, B. A.
(2001)
Gene Expr.
9,
265-281[Medline]
[Order article via Infotrieve]
|
| 32.
|
Qiu, M.,
Bulfone, A.,
Martinez, S.,
Meneses, J. J.,
Shimamura, K.,
Pedersen, R. A.,
and Rubenstein, J. L. R.
(1995)
Genes Dev.
9,
2523-2538[Abstract/Free Full Text]
|
| 33.
|
Thomas, B. L.,
Liu, J. K.,
Rubenstein, J. L. R.,
and Sharpe, P. T.
(2000)
Development
127,
217-224[Abstract]
|
| 34.
|
Liu, J. K.,
Ghattas, I.,
Liu, S.,
Chen, S.,
and Rubenstein, J. L. R.
(1997)
Dev. Dyn.
210,
498-512[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Amendt, B. A.,
Sutherland, L. B.,
and Russo, A. F.
(1999)
Mol. Cel. Biol.
19,
7001-7010[Abstract/Free Full Text]
|
| 36.
|
Padanilam, B. J.,
Stadler, H. S.,
Mills, K. A.,
McLeod, L. B.,
Solursh, M.,
Lee, B.,
Ramirez, F.,
Buetow, K. H.,
and Murray, J. C.
(1992)
Hum. Mol. Genet.
1,
407-410[Abstract/Free Full Text]
|
| 37.
|
Smidt, M. P.,
Cox, J. J.,
van Schaick, H. S. A.,
Coolen, M.,
Schepers, J.,
van der Kleij, A. M.,
and Burbach, J. P. H.
(2000)
J. Neurochem.
75,
1818-1825[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Lowen, M.,
Scott, G.,
and Zwollo, P.
(2001)
J. Biol. Chem.
276,
42565-42574[Abstract/Free Full Text]
|
| 39.
|
Day, R. N.,
and Day, K. H.
(1994)
Mol. Endocrinol.
8,
374-381[Abstract/Free Full Text]
|
| 40.
|
Szeto, D. P.,
Ryan, A. K.,
O'Connell, S. M.,
and Rosenfeld, M. G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7706-7710[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Footz, F. Idrees, M. Acharya, K. Kozlowski, and M. A. Walter
Analysis of Mutations of the PITX2 Transcription Factor Found in Patients with Axenfeld-Rieger Syndrome
Invest. Ophthalmol. Vis. Sci.,
June 1, 2009;
50(6):
2599 - 2606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Venugopalan, M. A. Amen, J. Wang, L. Wong, A. C. Cavender, R. N. D'Souza, M. Akerlund, S. L. Brody, T. A. Hjalt, and B. A. Amendt
Novel expression and transcriptional regulation of FoxJ1 during oro-facial morphogenesis
Hum. Mol. Genet.,
December 1, 2008;
17(23):
3643 - 3654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Viviani Anselmi, V Novelli, R Roncarati, A Malovini, R Bellazzi, R Bronzini, G Marchese, G Condorelli, A S Montenero, and A A Puca
Association of rs2200733 at 4q25 with atrial flutter/fibrillation diseases in an Italian population
Heart,
November 1, 2008;
94(11):
1394 - 1396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Lamba, V. Khivansara, A. C. D'Alessio, M. M. Santos, and D. J. Bernard
Paired-Like Homeodomain Transcription Factors 1 and 2 Regulate Follicle-Stimulating Hormone {beta}-Subunit Transcription through a Conserved cis-Element
Endocrinology,
June 1, 2008;
149(6):
3095 - 3108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Amen, H. M. Espinoza, C. Cox, X. Liang, J. Wang, T. M. E. Link, R. G. Brennan, J. F. Martin, and B. A. Amendt
Chromatin-associated HMG-17 is a major regulator of homeodomain transcription factor activity modulated by Wnt/{beta}-catenin signaling
Nucleic Acids Res.,
February 2, 2008;
36(2):
462 - 476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Guioli and R. Lovell-Badge
PITX2 controls asymmetric gonadal development in both sexes of the chick and can rescue the degeneration of the right ovary
Development,
December 1, 2007;
134(23):
4199 - 4208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Amen, X. Liu, U. Vadlamudi, G. Elizondo, E. Diamond, J. F. Engelhardt, and B. A. Amendt
PITX2 and {beta}-Catenin Interactions Regulate Lef-1 Isoform Expression
Mol. Cell. Biol.,
November 1, 2007;
27(21):
7560 - 7573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Diamond, M. Amen, Q. Hu, H. M. Espinoza, and B. A. Amendt
Functional interactions between Dlx2 and lymphoid enhancer factor regulate Msx2
Nucleic Acids Res.,
November 6, 2006;
34(20):
5951 - 5965.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Bidinost, M. Matsumoto, D. Chung, N. Salem, K. Zhang, D. W. Stockton, A. Khoury, A. Megarbane, B. A. Bejjani, and E. I. Traboulsi
Heterozygous and Homozygous Mutations in PITX3 in a Large Lebanese Family with Posterior Polar Cataracts and Neurodevelopmental Abnormalities.
Invest. Ophthalmol. Vis. Sci.,
April 1, 2006;
47(4):
1274 - 1280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. B. Berry, M. A. Lines, J. M. Oas, T. Footz, D. A. Underhill, P. J. Gage, and M. A. Walter
Functional interactions between FOXC1 and PITX2 underlie the sensitivity to FOXC1 gene dose in Axenfeld-Rieger syndrome and anterior segment dysgenesis
Hum. Mol. Genet.,
March 15, 2006;
15(6):
905 - 919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Evans and P. J. Gage
Expression of the homeobox gene Pitx2 in neural crest is required for optic stalk and ocular anterior segment development
Hum. Mol. Genet.,
November 15, 2005;
14(22):
3347 - 3359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bassham and J. H. Postlethwait
The evolutionary history of placodes: a molecular genetic investigation of the larvacean urochordate Oikopleura dioica
Development,
October 1, 2005;
132(19):
4259 - 4272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Vadlamudi, H. M. Espinoza, M. Ganga, D. M. Martin, X. Liu, J. F. Engelhardt, and B. A. Amendt
PITX2, {beta}-catenin and LEF-1 interact to synergistically regulate the LEF-1 promoter
J. Cell Sci.,
March 15, 2005;
118(6):
1129 - 1137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Toro, I. Saadi, A. Kuburas, M. Nemer, and A. F. Russo
Cell-specific Activation of the Atrial Natriuretic Factor Promoter by PITX2 and MEF2A
J. Biol. Chem.,
December 10, 2004;
279(50):
52087 - 52094.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Schubert, E. Kardash, M. A. Khan, T. Cheusova, K. Kilian, M. Wegner, and S. Hashemolhosseini
Interaction, Cooperative Promoter Modulation, and Renal Colocalization of GCMa and Pitx2
J. Biol. Chem.,
November 26, 2004;
279(48):
50358 - 50365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Lines, K. Kozlowski, S. C. Kulak, R. R. Allingham, E. Heon, R. Ritch, A. V. Levin, M. B. Shields, K. F. Damji, A. Newlin, et al.
Characterization and Prevalence of PITX2 Microdeletions and Mutations in Axenfeld-Rieger Malformations
Invest. Ophthalmol. Vis. Sci.,
March 1, 2004;
45(3):
828 - 833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Liu, J. Selever, M.-F. Lu, and J. F. Martin
Genetic dissection of Pitx2 in craniofacial development uncovers new functions in branchial arch morphogenesis, late aspects of tooth morphogenesis and cell migration
Development,
December 22, 2003;
130(25):
6375 - 6385.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, H. Zhao, X. Zhang, and H. Feng
Novel Identification of a Four-base-pair Deletion Mutation in PITX2 in a Rieger Syndrome Family
Journal of Dental Research,
December 1, 2003;
82(12):
1008 - 1012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Schausi, C. Tiffoche, and M.-L. Thieulant
Regulation of the Intronic Promoter of Rat Estrogen Receptor {alpha} Gene, Responsible for Truncated Estrogen Receptor Product-1 Expression
Endocrinology,
July 1, 2003;
144(7):
2845 - 2855.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ganga, H. M. Espinoza, C. J. Cox, L. Morton, T. A. Hjalt, Y. Lee, and B. A. Amendt
PITX2 Isoform-specific Regulation of Atrial Natriuretic Factor Expression: SYNERGISM AND REPRESSION WITH Nkx2.5
J. Biol. Chem.,
June 13, 2003;
278(25):
22437 - 22445.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Kamnasaran, W J Muir, M A Ferguson-Smith, and D W Cox
Disruption of the neuronal PAS3 gene in a family affected with schizophrenia
J. Med. Genet.,
May 1, 2003;
40(5):
325 - 332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Shaw, X. Zhang, A. F. Russo, B. A. Amendt, S. Henderson, and V. Williams
Homeobox Protein, Hmx3, in Postnatally Developing Rat Submandibular Glands
J. Histochem. Cytochem.,
March 1, 2003;
51(3):
385 - 396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. I. Suszko, D. J. Lo, H. Suh, S. A. Camper, and T. K. Woodruff
Regulation of the Rat Follicle-Stimulating Hormone {beta}-Subunit Promoter by Activin
Mol. Endocrinol.,
March 1, 2003;
17(3):
318 - 332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Liu, W. Liu, J. Palie, M. F. Lu, N. A. Brown, and J. F. Martin
Pitx2c patterns anterior myocardium and aortic arch vessels and is required for local cell movement into atrioventricular cushions
Development,
January 11, 2002;
129(21):
5081 - 5091.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. CAMPIONE, L. ACOSTA, S. MARTINEZ, J.M. ICARDO, A. ARANEGA, and D. FRANCO
Pitx2 and Cardiac Development: A Molecular Link between Left/Right Signaling and Congenital Heart Disease
Cold Spring Harb Symp Quant Biol,
January 1, 2002;
67(0):
89 - 96.
[Abstract]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|